6VUZ | pdb_00006vuz

Crystal structure of Eis from Mycobacterium tuberculosis in complex with inhibitor SGT353


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.65 Å
  • R-Value Free: 
    0.224 (Depositor), 0.216 (DCC) 
  • R-Value Work: 
    0.178 (Depositor) 
  • R-Value Observed: 
    0.180 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6VUZ

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis fromMycobacterium tuberculosis.

Punetha, A.Ngo, H.X.Holbrook, S.Y.L.Green, K.D.Willby, M.J.Bonnett, S.A.Krieger, K.Dennis, E.K.Posey, J.E.Parish, T.Tsodikov, O.V.Garneau-Tsodikova, S.

(2020) ACS Chem Biol 15: 1581-1594

  • DOI: https://doi.org/10.1021/acschembio.0c00184
  • Primary Citation Related Structures: 
    6VUR, 6VUS, 6VUT, 6VUU, 6VUW, 6VUX, 6VUY, 6VUZ, 6VV0, 6VV1, 6VV2, 6VV3

  • PubMed Abstract: 

    The enhanced intracellular survival (Eis) protein of Mycobacterium tuberculosis ( Mtb ) is a versatile acetyltransferase that multiacetylates aminoglycoside antibiotics abolishing their binding to the bacterial ribosome. When overexpressed as a result of promoter mutations, Eis causes drug resistance. In an attempt to overcome the Eis-mediated kanamycin resistance of Mtb , we designed and optimized structurally unique thieno[2,3- d ]pyrimidine Eis inhibitors toward effective kanamycin adjuvant combination therapy. We obtained 12 crystal structures of enzyme-inhibitor complexes, which guided our rational structure-based design of 72 thieno[2,3- d ]pyrimidine analogues divided into three families. We evaluated the potency of these inhibitors in vitro as well as their ability to restore the activity of kanamycin in a resistant strain of Mtb , in which Eis was upregulated. Furthermore, we evaluated the metabolic stability of 11 compounds in vitro . This study showcases how structural information can guide Eis inhibitor design.


  • Organizational Affiliation
    • Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536-0596, United States.

Macromolecule Content 

  • Total Structure Weight: 46.84 kDa 
  • Atom Count: 3,261 
  • Modeled Residue Count: 396 
  • Deposited Residue Count: 422 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
N-acetyltransferase Eis422Mycobacterium tuberculosis H37RvMutation(s): 1 
Gene Names: eisRv2416cMTCY253.04
EC: 2.3.1
UniProt
Find proteins for P9WFK7 (Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv))
Explore P9WFK7 
Go to UniProtKB:  P9WFK7
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP9WFK7
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
RMS
(Subject of Investigation/LOI)

Query on RMS



Download:Ideal Coordinates CCD File
B [auth A]2-{[3-(piperidin-1-yl)propyl]sulfanyl}-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-amine
C17 H24 N4 S2
LFHQZKLJPPVEJC-UHFFFAOYSA-N
PEG

Query on PEG



Download:Ideal Coordinates CCD File
C [auth A],
F [auth A]
DI(HYDROXYETHYL)ETHER
C4 H10 O3
MTHSVFCYNBDYFN-UHFFFAOYSA-N
SO4

Query on SO4



Download:Ideal Coordinates CCD File
E [auth A],
G [auth A]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
GOL

Query on GOL



Download:Ideal Coordinates CCD File
D [auth A]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.65 Å
  • R-Value Free:  0.224 (Depositor), 0.216 (DCC) 
  • R-Value Work:  0.178 (Depositor) 
  • R-Value Observed: 0.180 (Depositor) 
Space Group: H 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 175.472α = 90
b = 175.472β = 90
c = 123.082γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
PDB_EXTRACTdata extraction
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)United StatesAI090048

Revision History  (Full details and data files)

  • Version 1.0: 2020-06-03
    Type: Initial release
  • Version 1.1: 2020-07-01
    Changes: Database references
  • Version 1.2: 2023-10-11
    Changes: Data collection, Database references, Refinement description